| Literature DB >> 24381505 |
Byung Tae Park1, Byung Sun Kim1, Heajin Park1, Jaehoon Jeong1, Hanbit Hyun1, Hye Seong Hwang1, Ha Hyung Kim1.
Abstract
We recently reported a Philyra pisum lectin (PPL) that exerts mitogenic effects on human lymphocytes, and its molecular characterization. The present study provides a more detailed characterization of PPL based on the results from a monosaccharide analysis indicating that PPL is a glycoprotein, and circular dichroism spectra revealing its estimated α-helix, β-sheet, β-turn, and random coil contents to be 14.0%, 39.6%, 15.8%, and 30.6%, respectively. These contents are quite similar to those of deglycosylated PPL, indicating that glycans do not affect its intact structure. The binding properties to different pathogen-associated molecular patterns were investigated with hemagglutination inhibition assays using lipoteichoic acid from Gram-positive bacteria, lipopolysaccharide from Gram-negative bacteria, and both mannan and β-1,3-glucan from fungi. PPL binds to lipoteichoic acids and mannan, but not to lipopolysaccharides or β-1,3-glucan. PPL exerted no significant antiproliferative effects against human breast or bladder cancer cells. These results indicate that PPL is a glycoprotein with a lipoteichoic acid or mannan-binding specificity and which contains low and high proportions of α-helix and β-structures, respectively. These properties are inherent to the innate immune system of P. pisum and indicate that PPL could be involved in signal transmission into Gram-positive bacteria or fungi.Entities:
Keywords: Antiproliferative activity; Deglycosylation; Lectin; Pathogen-associated molecular patterns; Secondary structure
Year: 2013 PMID: 24381505 PMCID: PMC3874443 DOI: 10.4196/kjpp.2013.17.6.547
Source DB: PubMed Journal: Korean J Physiol Pharmacol ISSN: 1226-4512 Impact factor: 2.016
Fig. 1Monosaccharide analysis of PPL using HPAEC-PAD with CarboPac PA10 and AminoTrap columns. (A) Monosaccharide standards and (B) acid hydrolysate of PPL.
Results of hemagglutination inhibition assays of PPL for different PAMPs
aMinimum inhibition concentration representing the reciprocal of the minimal dilution for inhibition in ICR mouse erythrocytes.
bNo inhibition was observed at concentrations up to 500 µg/ml.
Fig. 2CD spectra (at pH 8.0) of PPL and deglycosylated PPL in the far-UV region.
In vitro antiproliferative activity (quantified as the percentage viability) of PPL on human cancer cell lines
Data represent mean±SD values (n=3).